Feasibility Study to Evaluate Therapeutic Ultrasound (TUS) to Acutely Increase the Perfusion in Peripheral Arterial Disease (PAD) (Waltz)
A Prospective, Non-significant Risk, Feasibility Study to Evaluate Serial Applications of VibratoSleeve Therapy to Acutely Increase the Perfusion in Peripheral Arterial Disease (PAD) Subjects 65 Years of Age and Older
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Bisrat Woldemichael
- Phone Number: 213-921-0588
- Email: bisrat@vibratomedical.com
Study Contact Backup
- Name: Juliana Elstad
- Email: juliana@vibratomedical.com
Study Locations
-
-
California
-
Orange, California, United States, 92868
- Vascular & Interventional Specialists of Orange County
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 65
- Diagnosis of PAD.
- Claudication symptoms in Rutherford class 1,2, or 3 as determined by the investigator.
Exclusion Criteria:
- Prior stenting in posterior tibial artery.
- Re-vascularization procedure within 30 days prior to enrollment in the study.
- Ulcers, cellulitis, or skin breakdown in treatment areas (posterior calf).
- History or diagnosis of severe chronic venous insufficiency.
- Acute limb ischemia within 30 days prior to treatment.
- History or diagnosis of deep venous thrombosis below the knee in treatment leg.
- Any conditions that, in the opinion of the investigator, may render the subject unable to complete the study or lead to difficulties for subject compliance with study requirements, or could confound study data.
- Subject's enrollment in another investigational study that has not completed the required primary endpoint follow-up period.
stenting in posterior tibial artery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TUS Therapy
These subjects will undergo treatments with the Vibrato Sleeve TUS device.
|
The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Acute Flow Rate Difference During TUS Treatment Sessions
Time Frame: Baseline to end of treatment, an average of 1 month
|
Percent change in perfusion measured by FlowMet calculated between baseline and after final treatment.
|
Baseline to end of treatment, an average of 1 month
|
|
Tissue Oxygen Saturation (StO2)
Time Frame: Through study completion, an average of 1 month
|
Calculate changes in tissue oxygen saturation (StO2) measured non-invasively by Clarifi spatial frequency domain imaging system, compared from baseline to during and immediately post-treatment.
|
Through study completion, an average of 1 month
|
|
Ankle Brachial Index (ABI)
Time Frame: Baseline to end of treatment, an average of 1 month
|
ABI is ratio that compares blood pressure in the arm to blood pressure in the ankle.
It is a measurement of the extent of peripheral arterial disease.
|
Baseline to end of treatment, an average of 1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Device and Procedure-related Adverse Events
Time Frame: Through study completion, an average of 1 month
|
Number of adverse events related to the VibratoSleeve device or study procedure occurring throughout the duration of the study.
|
Through study completion, an average of 1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 022-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.